The Pharma LCA Consortium and AllocNow launch PharmaLCA, a software platform making standard compliant Life Cycle Assessments accessible

Backed by twelve leading pharmaceutical companies, PharmaLCA puts Life Cycle Assessments (LCA) within reach of the entire pharmaceutical value chain – creating the foundation for reliable product-level environmental profiles.

MILAN, 6 October 2026: Today, the Pharma LCA Consortium and AllocNow are unveiling PharmaLCA, the software endorsed by the Consortium's twelve member companies to accelerate industry-wide adoption of PAS 2090 [1]. Published by the British Standards Institution (BSI) at the end of 2025 and shaped by more than 475 stakeholders across 35 countries, PAS 2090 is the first international standard to give the pharmaceutical sector a harmonised method for measuring and communicating the environmental impact of its products. PharmaLCA has accessibility built into the core of the software, making it easier for non-technical professionals at companies including manufacturers, suppliers, and small pharmaceutical companies, to create robust environmental assessments.

PharmaLCA will be showcased by the Pharma LCA Consortium and AllocNow for the first time at CPHI Milan, on 6 October 2026 at the Sustainability Spotlight Stage and on 7 October 2026 at the CPHI Sustainability Summit.

Why this matters for the industry

The healthcare sector accounts for approximately 5% of global greenhouse gas emissions [2] and for many pharmaceutical products the majority of their environmental footprint [3] is in the manufacturing process. Understanding where the environmental drivers arise is therefore key in identifying effective opportunities for improvement and a strategic priority for many pharmaceutical companies. By making robust LCA studies more accessible, PharmaLCA aims to help the pharmaceutical stakeholders to develop a practical understanding of their key environmental drivers and identify targeted, evidence-based opportunities to improve environmental performance and advance their sustainability programmes.

What PharmaLCA offers

PharmaLCA runs pharmaceutical product end-to-end assessments covering all 16 environmental impact categories of the European Commission Product Environmental Footprint methodology (PEF) in line with the requirements of PAS 2090. The software has successfully undergone an independent evaluation by TÜV SÜD based on the requirements of PAS 2090. PharmaLCA is offered through a free Starter Plan and a paid Professional Plan, providing flexibility to meet different users' needs. As a web-based solution, PharmaLCA requires no installation and is designed to support all stakeholders across the pharmaceutical value chain, from suppliers and contract manufacturers to sustainability professionals regardless of their level of Life Cycle Assessment experience.

Sarah Arias Zeballos, Global Eco-design Leader and PharmaLCA Tool Lead, Sanofi, on behalf of the Pharma LCA Consortium

Where PharmaLCA goes from here

PharmaLCA is more than LCA software. Developed in collaboration with the Pharma LCA Consortium and external testers, it is building a shared foundation for environmental measurement across the pharmaceutical value chain. Aligned with PAS 2090, PharmaLCA will continue to evolve with industry needs and emerging environmental requirements.

Daniel Bochnitschek, Co-Founder, AllocNow

For more information: PharmaLCA https://www.pharmalca.com/

Media Contacts

Pharma LCA Consortium: Daniel Witte, SLR Consulting, daniel.witte@slrconsulting.com.

AllocNow: Sebastian Schulze, AllocNow GmbH, s.schulze@allocnow.com.

References

[1] Pharmaceutical products – Product category rules for environmental Life Cycle Assessments – Specification PAS 2090:2025. Available at: https://knowledge.bsigroup.com/products/pharmaceutical-products-product-category-rules-for-life-cycle-assessments-specification (accessed 1 October 2026).

[2] WHO, Measuring greenhouse gas emissions in health systems. Available at: https://www.who.int/publications/i/item/9789240118423 (accessed 1 October 2026).

[3] BSI 2090 use case, GSK pilot use case available at: PAS 2090 pilot use case - GSK | BSI, Sanofi pilot use case available at: PAS 2090 Pilot Use Case - Sanofi | BSI and Novo pilot use case available at: PAS 2090 pilot use case - Novo Nordisk | BSI (accessed 1 October 2026).